The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
The findings suggested that genomic surveillance of Barrett's esophagus could identify patients who will progress years in advance and enable earlier treatment.
The firm will use the proceeds to support commercialization, regulatory, and product development activities, as well as for general working capital purposes.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
Investigators reported on how ctDNA, measured using Natera's patient-specific Signatera assays, corresponded to a patient's disease progression and other biomarkers.
The test detects methylation status at 31 sites and is used to determine elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease.
